{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:59:18Z","timestamp":1790895558768,"version":"4.1.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204544"],"award-info":[{"award-number":["82204544"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["20224Y0121"],"award-info":[{"award-number":["20224Y0121"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.addr.2024.115447","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:29:23Z","timestamp":1726187363000},"page":"115447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives"],"prefix":"10.1016","volume":"214","author":[{"given":"Wen Yao","family":"Mak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aole","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2024.115447_b0005","doi-asserted-by":"crossref","first-page":"e0199121","DOI":"10.1128\/aac.01991-21","article-title":"Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed","volume":"66","author":"Butler","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.addr.2024.115447_b0010","series-title":"2021 Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis","author":"Gigante","year":"2021"},{"key":"10.1016\/j.addr.2024.115447_b0015","series-title":"2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline","author":"Antibacterial Agents in Clinical Development","year":"2019"},{"key":"10.1016\/j.addr.2024.115447_b0020","doi-asserted-by":"crossref","first-page":"e0236604","DOI":"10.1371\/journal.pone.0236604","article-title":"A novel pre-clinical antibacterial pipeline database","volume":"15","author":"Paulin","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2024.115447_b0025","unstructured":"World Health Organization, 2018 Update of Antibacterial Agents in Clinical Development World Health Organization, Geneva, 2018."},{"key":"10.1016\/j.addr.2024.115447_b0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-023-00692-8","article-title":"Accelerating antiviral drug discovery: lessons from COVID-19","volume":"22","author":"von Delft","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2024.115447_b0035","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","article-title":"Review: Role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making","volume":"39","author":"Madabushi","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2024.115447_b0040","unstructured":"FDA Guidance for Industry: providing clinical evidence of effectiveness for human drug and biologic products Food and Drug Administration Rockville, 1998."},{"key":"10.1016\/j.addr.2024.115447_b0045","unstructured":"US FDA, Population Pharmacokinetics: Guidance for Industry, US Food and Drug Administration, Maryland, 2022."},{"key":"10.1016\/j.addr.2024.115447_b0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/psp4.12365","article-title":"PDUFA VI: It Is Time to Unleash the Full Potential of Model-Informed Drug Development","volume":"8","author":"Jain","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2024.115447_b0055","doi-asserted-by":"crossref","unstructured":"EFPIA MID3 Workgroup, S.F. Marshall, R. Burghaus, V. Cosson, S.Y. Cheung, M. Chenel, O. DellaPasqua, N. Frey, B. Hamren, L. Harnisch, F. Ivanow, T. Kerbusch, J. Lippert, P.A. Milligan, S. Rohou, A. Staab, J.L. Steimer, C. Tornoe, S.A. Visser, Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation, CPT Pharmacometrics Syst Pharmacol, 5 (2016) 93-122.","DOI":"10.1002\/psp4.12049"},{"key":"10.1016\/j.addr.2024.115447_b0060","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/cpt.2198","article-title":"Model-informed drug development for anti-infectives: state of the art and future","volume":"109","author":"Rayner","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2024.115447_b0065","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2024.115447_b0070","doi-asserted-by":"crossref","unstructured":"\u2022\u2022I.K. Minichmayr, V. Aranzana-Climent, L.E. Friberg, Pharmacokinetic\/pharmacodynamic models for time courses of antibiotic effects, Int. J. Antimicrob Agents, 60 (2022) 106616.","DOI":"10.1016\/j.ijantimicag.2022.106616"},{"key":"10.1016\/j.addr.2024.115447_b0075","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cmi.2017.11.023","article-title":"Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations","volume":"24","author":"Brill","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.addr.2024.115447_b0080","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","article-title":"Therapeutic host-directed strategies to improve outcome in tuberculosis","volume":"13","author":"Young","year":"2020","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2024.115447_b0085","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","volume":"20","author":"Dartois","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2024.115447_b0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12916-021-02212-0","article-title":"Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients","volume":"20","author":"Sun","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.addr.2024.115447_b0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41576-020-00297-6","article-title":"Host genetics and infectious disease: new tools, insights and translational opportunities","volume":"22","author":"Kwok","year":"2021","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.addr.2024.115447_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106620","article-title":"Pharmacometrics in tuberculosis: progress and opportunities","volume":"60","author":"Wilkins","year":"2022","journal-title":"Int. J. Antimicrob Agents"},{"key":"10.1016\/j.addr.2024.115447_b0105","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4155\/fmc.10.224","article-title":"In vitro pharmacokinetic\/pharmacodynamic models in anti-infective drug development: focus on TB","volume":"2","author":"Vaddady","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.addr.2024.115447_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3851\/IMP1915","article-title":"Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children","volume":"17","author":"Zhang","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.addr.2024.115447_b0115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41591-020-0770-2","article-title":"Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions","volume":"26","author":"Ordonez","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2024.115447_b0120","doi-asserted-by":"crossref","first-page":"1067295","DOI":"10.3389\/fphar.2023.1067295","article-title":"Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development","volume":"14","author":"Ayoun Alsoud","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2024.115447_b0125","doi-asserted-by":"crossref","DOI":"10.1007\/s10928-022-09811-1","article-title":"Current practices for QSP model assessment: an IQ consortium survey","author":"Chan","year":"2022","journal-title":"J. Pharmacokinet. Pharmcodyn."},{"key":"10.1016\/j.addr.2024.115447_b0130","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2024.115447_b0135","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000087453","article-title":"From Atoxyl to Salvarsan: searching for the magic bullet","volume":"51","author":"Riethmiller","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.addr.2024.115447_b0140","unstructured":"A. Fleming, Nobel Lecture, Nobel Prize Outreach AB 2023, NobelPrize.org, 2023."},{"key":"10.1016\/j.addr.2024.115447_b0145","series-title":"Der Blutspiegel","author":"Dost","year":"1953"},{"key":"10.1016\/j.addr.2024.115447_b0150","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s15010-009-7108-9","article-title":"A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints","volume":"37","author":"Dalhoff","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.addr.2024.115447_b0155","unstructured":"A History of CLSI's Work on Antimicrobial Susceptibility Testing, CLSI, 2023."},{"key":"10.1016\/j.addr.2024.115447_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.770518","article-title":"Limitations of antibiotic MIC-based PK-PD metrics: looking back to move forward","volume":"12","author":"Landersdorfer","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2024.115447_b0165","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1128\/AAC.44.6.1655-1659.2000","article-title":"Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir","volume":"44","author":"Drusano","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.addr.2024.115447_b0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.45.1.13-22.2001","article-title":"Use of preclinical data for selection of a phase II\/III dose for evernimicin and identification of a preclinical MIC breakpoint","volume":"45","author":"Drusano","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.addr.2024.115447_b0175","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1369-5274(00)00132-6","article-title":"Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time","volume":"3","author":"Dudley","year":"2000","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.addr.2024.115447_b0180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0732-8893(00)00185-1","article-title":"The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae","volume":"38","author":"Ambrose","year":"2000","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.addr.2024.115447_b0185","series-title":"Clinical Trial Simulations: Applications and Trends, 1","author":"Peck","year":"2011"},{"key":"10.1016\/j.addr.2024.115447_b0190","unstructured":"World Health Organization, WHO publishes list of bacteria for which new antibiotics are urgently needed, Geneva, 2017."},{"key":"10.1016\/j.addr.2024.115447_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10101310","article-title":"Bacterial antibiotic resistance: the most critical pathogens","volume":"10","author":"Mancuso","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.addr.2024.115447_b0200","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4103\/joacp.JOACP_349_15","article-title":"Action and resistance mechanisms of antibiotics: a guide for clinicians","volume":"33","author":"Kapoor","year":"2017","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2024.115447_b0205","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/aje\/kwt017","article-title":"A modeling framework for the evolution and spread of antibiotic resistance: literature review and model categorization","volume":"178","author":"Spicknall","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.addr.2024.115447_b0210","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/0040-5809(87)90053-0","article-title":"Antibiotic exposure and resistance in mixed bacterial populations","volume":"32","author":"Garber","year":"1987","journal-title":"Theor. Popul. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0215","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jps.2600830711","article-title":"Pharmacodynamic modeling of bacterial kinetics: \u03b2-lactam antibiotics against Escherichia colj","volume":"83","author":"Li","year":"1994","journal-title":"J. Pharm Sci."},{"key":"10.1016\/j.addr.2024.115447_b0220","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1073\/pnas.082188899","article-title":"Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria","volume":"99","author":"Smith","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2024.115447_b0225","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3201\/eid0904.020213","article-title":"Bacterial resistance to penicillin G by decreased affinity of penicillin-binding proteins: a mathematical model","volume":"9","author":"Temime","year":"2003","journal-title":"Emerg Infect. Dis."},{"key":"10.1016\/j.addr.2024.115447_b0230","doi-asserted-by":"crossref","first-page":"13285","DOI":"10.1073\/pnas.0402298101","article-title":"Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals","volume":"101","author":"Bergstrom","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2024.115447_b0235","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s11538-012-9731-3","article-title":"Modeling non-inherited antibiotic resistance","volume":"74","author":"Bootsma","year":"2012","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0240","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00285-013-0668-4","article-title":"Modeling the role of altruism of antibiotic-resistant bacteria","volume":"68","author":"Wang","year":"2014","journal-title":"J. Math. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0245","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1128\/AAC.00694-11","article-title":"Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.addr.2024.115447_b0250","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/acs.molpharmaceut.9b00968","article-title":"Model-informed drug development in pulmonary delivery: semimechanistic pharmacokinetic-pharmacodynamic modeling for evaluation of treatments against chronic pseudomonas aeruginosa lung infections","volume":"17","author":"Sou","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2024.115447_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020246","article-title":"Application of semi-mechanistic pharmacokinetic and pharmacodynamic model in antimicrobial resistance","volume":"14","author":"Mi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2024.115447_b0260","doi-asserted-by":"crossref","first-page":"e0228138","DOI":"10.1371\/journal.pone.0228138","article-title":"The effect of enrofloxacin on enteric Escherichia coli: Fitting a mathematical model to in vivo data","volume":"15","author":"Erwin","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2024.115447_b0265","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/jac\/dkv488","article-title":"Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK\/PD model","volume":"71","author":"Mohamed","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2024.115447_b0270","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/s41467-017-01929-y","article-title":"A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions","volume":"8","author":"Wicha","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2024.115447_b0275","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/psp4.12312","article-title":"Mechanism-based disease progression model describing host-pathogen interactions during the pathogenesis of Acinetobacter baumannii Pneumonia","volume":"7","author":"Diep","year":"2018","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2024.115447_b0280","first-page":"407","article-title":"Mathematical model for the growth of Mycobacterium tuberculosis in the granuloma","volume":"15","author":"Ibarguen-Mondragon","year":"2018","journal-title":"Math. Biosci. Eng."},{"key":"10.1016\/j.addr.2024.115447_b0285","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.mbs.2013.08.005","article-title":"On the interactions of sensitive and resistant Mycobacterium tuberculosis to antibiotics","volume":"246","author":"Ibarguen-Mondragon","year":"2013","journal-title":"Math. Biosci."},{"key":"10.1016\/j.addr.2024.115447_b0290","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.apm.2019.06.017","article-title":"Stability and periodic solutions for a model of bacterial resistance to antibiotics caused by mutations and plasmids","volume":"76","author":"Ibarguen-Mondragon","year":"2019","journal-title":"App. Math. Model."},{"key":"10.1016\/j.addr.2024.115447_b0295","doi-asserted-by":"crossref","first-page":"e1008107","DOI":"10.1371\/journal.pcbi.1008107","article-title":"Mathematical model and tool to explore shorter multidrug therapy options for active pulmonary tuberculosis","volume":"16","author":"Fors","year":"2020","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0300","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13756-018-0406-1","article-title":"Send more data: a systematic review of mathematical models of antimicrobial resistance","volume":"7","author":"Birkeg\u00e5rd","year":"2018","journal-title":"Antimicrob Resist. Infect. Control"},{"key":"10.1016\/j.addr.2024.115447_b0305","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ecolmodel.2014.01.018","article-title":"Towards better modelling and decision support: documenting model development, testing, and analysis using TRACE","volume":"280","author":"Grimm","year":"2014","journal-title":"Ecol. Model"},{"key":"10.1016\/j.addr.2024.115447_b0310","doi-asserted-by":"crossref","unstructured":"F. Zanini, V. Puller, J. Brodin, J. Albert, R.A. Neher, In vivo mutation rates and the landscape of fitness costs of HIV-1, Virus Evol, 3 (2017) vex003.","DOI":"10.1093\/ve\/vex003"},{"key":"10.1016\/j.addr.2024.115447_b0315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fcimb.2019.00042","article-title":"How viral and intracellular bacterial pathogens reprogram the metabolism of host cells to allow their intracellular replication","volume":"9","author":"Eisenreich","year":"2019","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.addr.2024.115447_b0320","series-title":"Highly Active Antiretroviral Therapy (HAART)","author":"Eggleton","year":"2023"},{"key":"10.1016\/j.addr.2024.115447_b0325","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.addr.2024.115447_b0330","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: a systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2024.115447_b0335","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00066-17","article-title":"Kinetic modeling of virus growth in cells","volume":"82","author":"Yin","year":"2018","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.addr.2024.115447_b0340","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0303-2647(75)90031-3","article-title":"A new aspect of the RNA bacteriophages translation control mechanism","volume":"7","author":"Knijnenburg","year":"1975","journal-title":"Biosystems"},{"key":"10.1016\/j.addr.2024.115447_b0345","doi-asserted-by":"crossref","first-page":"11005","DOI":"10.1021\/bi00110a001","article-title":"The hypercycle. Coupling of RNA and protein biosynthesis in the infection cycle of an RNA bacteriophage","volume":"30","author":"Eigen","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2024.115447_b0350","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0290(19970720)55:2<375::AID-BIT15>3.0.CO;2-G","article-title":"Intracellular kinetics of a growing virus: a genetically structured simulation for bacteriophage T7","volume":"55","author":"Endy","year":"1997","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2024.115447_b0355","unstructured":"GBDHB Collaborators, Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019, Lancet Gastroenterol. Hepatol., 7 (2022) 796-829."},{"key":"10.1016\/j.addr.2024.115447_b0360","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coisb.2019.10.003","article-title":"Within-host mathematical models of hepatitis B virus infection: past, present, and future","volume":"18","author":"Goyal","year":"2019","journal-title":"Curr. Opin. Syst. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0365","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1084\/jem.193.7.847","article-title":"Kinetics of acute hepatitis B virus infection in humans","volume":"193","author":"Whalley","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2024.115447_b0370","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis B virus infection","volume":"93","author":"Nowak","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2024.115447_b0375","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2004-828673","article-title":"Hepatitis B virus kinetics and mathematical modeling","volume":"24","author":"Perelson","year":"2004","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.addr.2024.115447_b0380","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1286-4579(02)01603-9","article-title":"Dynamics of hepatitis B virus infection","volume":"4","author":"Ribeiro","year":"2002","journal-title":"Microbes Infect."},{"key":"10.1016\/j.addr.2024.115447_b0385","doi-asserted-by":"crossref","first-page":"e1003730","DOI":"10.1371\/journal.pcbi.1003730","article-title":"Antibody responses during hepatitis B viral infection","volume":"10","author":"Ciupe","year":"2014","journal-title":"PLoS Comput. Biol"},{"key":"10.1016\/j.addr.2024.115447_b0390","doi-asserted-by":"crossref","first-page":"e50377","DOI":"10.1371\/journal.pone.0050377","article-title":"Mathematical modeling of triphasic viral dynamics in patients with HBeAg-positive chronic hepatitis B showing response to 24-week clevudine therapy","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2024.115447_b0395","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.22586","article-title":"Modeling complex decay profiles of hepatitis B virus during antiviral therapy","volume":"49","author":"Dahari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.addr.2024.115447_b0400","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0025-5564(94)90017-5","article-title":"A cellular model to explain the pathogenesis of infection by the hepatitis B virus","volume":"123","author":"Payne","year":"1994","journal-title":"Math. Biosci."},{"key":"10.1016\/j.addr.2024.115447_b0405","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jtbi.2010.10.024","article-title":"A mathematical model of the intracellular replication and within host evolution of hepatitis type B virus: Understanding the long time course of chronic hepatitis","volume":"269","author":"Nakabayashi","year":"2011","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0410","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jtbi.2016.02.008","article-title":"The intracellular dynamics of hepatitis B virus (HBV) replication with reproduced virion \u201cre-cycling\u201d","volume":"396","author":"Nakabayashi","year":"2016","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0415","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.chom.2010.06.014","article-title":"Viral latency and its regulation: lessons from the gamma-herpesviruses","volume":"8","author":"Speck","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2024.115447_b0420","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.addr.2024.115447_b0425","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.addr.2024.115447_b0430","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.cgh.2023.02.032","article-title":"New perspectives on development of curative strategies for chronic Hepatitis B","volume":"21","author":"Feld","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2024.115447_b0435","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/imr.12686","article-title":"Modeling the dynamics of hepatitis B infection, immunity, and drug therapy","volume":"285","author":"Ciupe","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.addr.2024.115447_b0440","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1423-0127-18-96","article-title":"Dynamics of HBV cccDNA expression and transcription in different cell growth phase","volume":"18","author":"Chong","year":"2011","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.addr.2024.115447_b0445","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.addr.2024.115447_b0450","doi-asserted-by":"crossref","DOI":"10.3390\/v9010018","article-title":"Control of Hepatitis B Virus by Cytokines","volume":"9","author":"Xia","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2024.115447_b0455","doi-asserted-by":"crossref","DOI":"10.3390\/v9110350","article-title":"The role of infected cell proliferation in the clearance of Acute HBV infection in humans","volume":"9","author":"Goyal","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2024.115447_b0460","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jtbi.2007.02.017","article-title":"Modeling the mechanisms of acute hepatitis B virus infection","volume":"247","author":"Ciupe","year":"2007","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0465","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1073\/pnas.0603626104","article-title":"The role of cells refractory to productive infection in acute hepatitis B viral dynamics","volume":"104","author":"Ciupe","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.addr.2024.115447_b0470","doi-asserted-by":"crossref","first-page":"8920","DOI":"10.1128\/JVI.00052-12","article-title":"Targeted DNA mutagenesis for the cure of chronic viral infections","volume":"86","author":"Schiffer","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.addr.2024.115447_b0475","doi-asserted-by":"crossref","first-page":"e1003131","DOI":"10.1371\/journal.pcbi.1003131","article-title":"Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach","volume":"9","author":"Schiffer","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0480","doi-asserted-by":"crossref","first-page":"S517","DOI":"10.1093\/cid\/ciac718","article-title":"Long-acting treatments for Hepatitis B","volume":"75","author":"Thomas","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2024.115447_b0485","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijantimicag.2016.05.016","article-title":"Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naive patients with chronic hepatitis B","volume":"48","author":"Boglione","year":"2016","journal-title":"Int. J. Antimicrob Agents"},{"key":"10.1016\/j.addr.2024.115447_b0490","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpba.2015.05.016","article-title":"UPLC-MS\/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients","volume":"114","author":"De Nicolo","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.addr.2024.115447_b0495","series-title":"Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment Guidance for Industry","author":"Fda","year":"2022"},{"key":"10.1016\/j.addr.2024.115447_b0500","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40262-016-0420-5","article-title":"Using population pharmacokinetic and pharmacodynamic analyses of entecavir in pediatric subjects to simplify dosing recommendations","volume":"55","author":"Chan","year":"2016","journal-title":"Clin. Pharmacokinet"},{"key":"10.1016\/j.addr.2024.115447_b0505","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1016\/j.csbj.2021.08.052","article-title":"A quantitative systems pharmacology model for acute viral hepatitis B","volume":"19","author":"Asin-Prieto","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.addr.2024.115447_b0510","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.epidem.2012.06.001","article-title":"Estimating influenza latency and infectious period durations using viral excretion data","volume":"4","author":"Cori","year":"2012","journal-title":"Epidemics"},{"key":"10.1016\/j.addr.2024.115447_b0515","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/infdis\/jiv260","article-title":"Interval between infections and viral hierarchy are determinants of viral interference following influenza virus infection in a ferret model","volume":"212","author":"Laurie","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2024.115447_b0520","doi-asserted-by":"crossref","first-page":"e1004334","DOI":"10.1371\/journal.pcbi.1004334","article-title":"Innate immunity and the inter-exposure interval determine the dynamics of secondary influenza virus infection and explain observed viral hierarchies","volume":"11","author":"Cao","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0525","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12985-017-0805-6","article-title":"Unexpected complexity in the interference activity of a cloned influenza defective interfering RNA","volume":"14","author":"Meng","year":"2017","journal-title":"Virol. J."},{"key":"10.1016\/j.addr.2024.115447_b0530","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.virusres.2015.11.016","article-title":"Modeling the intracellular replication of influenza A virus in the presence of defective interfering RNAs","volume":"213","author":"Laske","year":"2016","journal-title":"Virus Res."},{"key":"10.1016\/j.addr.2024.115447_b0535","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fmicb.2016.00326","article-title":"Propagation and characterization of influenza virus stocks that lack high levels of defective viral genomes and hemagglutinin mutations","volume":"7","author":"Xue","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2024.115447_b0540","unstructured":"PDUFA reauthorization performance goals and procedures for fiscal years 2018 through 2022."},{"key":"10.1016\/j.addr.2024.115447_b0545","unstructured":"[Technical guidelines for pharmacokinetic\/pharmacodynamic studies of antimicrobial drugs], National Medical Products Administraiton, 2022."},{"key":"10.1016\/j.addr.2024.115447_b0550","doi-asserted-by":"crossref","first-page":"eabl3836","DOI":"10.1126\/scitranslmed.abl3836","article-title":"Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy","volume":"14","author":"Uldrick","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2024.115447_b0555","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2024.115447_b0560","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.chom.2014.02.003","article-title":"Host immune response to infection and cancer: unexpected commonalities","volume":"15","author":"Goldszmid","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2024.115447_b0565","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nri.2017.69","article-title":"Heterogeneity in tuberculosis","volume":"17","author":"Cadena","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2024.115447_b0570","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.dmpk.2018.11.002","article-title":"Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development","volume":"34","author":"Glassman","year":"2019","journal-title":"Drug Metab. Pharmacokinet"},{"key":"10.1016\/j.addr.2024.115447_b0575","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/infdis\/jix211","article-title":"A. Infectious diseases society of, white paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs","volume":"216","author":"Boucher","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2024.115447_b0580","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ame2.12165","article-title":"Cancer models in preclinical research: a chronicle review of advancement in effective cancer research","volume":"4","author":"Sajjad","year":"2021","journal-title":"Animal Model Exp. Med."},{"key":"10.1016\/j.addr.2024.115447_b0585","doi-asserted-by":"crossref","first-page":"2178242","DOI":"10.1080\/22221751.2023.2178242","article-title":"Development of animal models for emerging infectious diseases by breaking the barrier of species susceptibility to human pathogens","volume":"12","author":"Rong","year":"2023","journal-title":"Emerg Microbes Infect."},{"key":"10.1016\/j.addr.2024.115447_b0590","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ame2.12020","article-title":"Choosing the right animal model for infectious disease research","volume":"1","author":"Swearengen","year":"2018","journal-title":"Animal Model Exp. Med."},{"key":"10.1016\/j.addr.2024.115447_b0595","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cpt.2021","article-title":"Physiologically based pharmacokinetic modeling of central nervous system pharmacokinetics of CDK4\/6 inhibitors to guide selection of drug and dosing regimen for brain cancer treatment","volume":"109","author":"Li","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2024.115447_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106345","article-title":"The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells","volume":"181","author":"Saleh","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2024.115447_b0605","article-title":"A minimal physiologically based pharmacokinetic model to characterize CNS distribution of metronidazole in neuro care ICU patients","volume":"11","author":"Chauzy","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.addr.2024.115447_b0610","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2023.07.040","article-title":"An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice","volume":"361","author":"Chou","year":"2023","journal-title":"J. Control Release"},{"key":"10.1016\/j.addr.2024.115447_b0615","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcibr1404664","article-title":"Parallels between cancer and infectious disease","volume":"371","author":"Hotchkiss","year":"2014","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.addr.2024.115447_b0620","doi-asserted-by":"crossref","first-page":"25945","DOI":"10.1038\/srep25945","article-title":"Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study","volume":"6","author":"Milani","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2024.115447_b0625","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.anaerobe.2016.05.009","article-title":"The microbiota and immune response during Clostridium difficile infection","volume":"41","author":"Buonomo","year":"2016","journal-title":"Anaerobe"},{"key":"10.1016\/j.addr.2024.115447_b0630","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.addr.2024.115447_b0635","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/psp4.12546","article-title":"QSP-IO: a quantitative systems pharmacology toolbox for mechanistic multiscale modeling for immuno-oncology applications","volume":"9","author":"Sove","year":"2020","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2024.115447_b0640","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2019.00924","article-title":"Quantitative mechanistic modeling in support of pharmacological therapeutics development in immuno-oncology","volume":"10","author":"Peskov","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2024.115447_b0645","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/psp4.12700","article-title":"Application of quantitative systems pharmacology to guide the optimal dosing of COVID-19 vaccines","volume":"10","author":"Giorgi","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2024.115447_b0650","doi-asserted-by":"crossref","first-page":"e2325","DOI":"10.1002\/rmv.2325","article-title":"Therapeutic roles of CAR T cells in infectious diseases: clinical lessons learnt from cancer","volume":"32","author":"Mohammadi","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.addr.2024.115447_b0655","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/psp4.12388","article-title":"Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells","volume":"8","author":"Stein","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2024.115447_b0660","doi-asserted-by":"crossref","unstructured":"A.M. Mc Laughlin, P.A. Milligan, C. Yee, M. Bergstrand, Model-informed drug development of autologous CAR-T cell therapy: strategies to optimize CAR-T cell exposure leveraging cell kinetic\/dynamic modeling, CPT Pharmacometrics Syst. Pharmacol., (2023).","DOI":"10.1002\/psp4.13011"},{"key":"10.1016\/j.addr.2024.115447_b0665","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1158\/1535-7163.MCT-19-1109","article-title":"Shaping functional avidity of CAR T cells: affinity, avidity, and antigen density that regulate response","volume":"20","author":"Greenman","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2024.115447_b0670","doi-asserted-by":"crossref","first-page":"1688616","DOI":"10.1080\/19420862.2019.1688616","article-title":"Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model","volume":"12","author":"Singh","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2024.115447_b0675","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/s12879-017-2683-3","article-title":"Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing","volume":"17","author":"Thorlund","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.addr.2024.115447_b0680","doi-asserted-by":"crossref","first-page":"e1006575","DOI":"10.1371\/journal.ppat.1006575","article-title":"In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell \u201ckick\u201d and \u201ckill\u201d in strategy for virus eradication","volume":"13","author":"Marsden","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2024.115447_b0685","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","article-title":"Getting the \u201cKill\u201d into \u201cShock and Kill\u201d: Strategies to Eliminate Latent HIV","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2024.115447_b0690","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.724767","article-title":"A review of using mathematical modeling to improve our understanding of bacteriophage, bacteria, and eukaryotic interactions","volume":"12","author":"Styles","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2024.115447_b0695","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chom.2019.06.004","article-title":"Non-traditional antibacterial therapeutic options and challenges","volume":"26","author":"Theuretzbacher","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2024.115447_b0700","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cmi.2023.01.021","article-title":"Pharmacokinetics\/pharmacodynamics of phage therapy: a major hurdle to clinical translation","volume":"29","author":"Nang","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.addr.2024.115447_b0705","first-page":"98","article-title":"Further considerations on how to improve phage therapy experimentation, practice, and reporting: pharmacodynamics perspectives","volume":"3","author":"Abedon","year":"2022","journal-title":"Phage (new Rochelle)"},{"key":"10.1016\/j.addr.2024.115447_b0710","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4161\/bact.1.2.15456","article-title":"Enumeration of bacteriophage particles: comparative analysis of the traditional plaque assay and real-time QPCR- and nanosight-based assays","volume":"1","author":"Anderson","year":"2011","journal-title":"Bacteriophage"},{"key":"10.1016\/j.addr.2024.115447_b0715","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.613529","article-title":"Analysis of selection methods to develop novel phage therapy cocktails against antimicrobial resistant clinical isolates of bacteria","volume":"12","author":"Haines","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2024.115447_b0720","doi-asserted-by":"crossref","first-page":"e13936","DOI":"10.15252\/emmm.202113936","article-title":"Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child","volume":"13","author":"Khatami","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.addr.2024.115447_b0725","doi-asserted-by":"crossref","DOI":"10.3390\/v11010010","article-title":"Interactions between bacteriophage, bacteria, and the mammalian immune system","volume":"11","author":"Van Belleghem","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2024.115447_b0730","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/03009734.2014.902878","article-title":"Phage therapy\u2013constraints and possibilities","volume":"119","author":"Nilsson","year":"2014","journal-title":"Ups J. Med. Sci."},{"key":"10.1016\/j.addr.2024.115447_b0735","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00756-19","article-title":"Quantitative models of phage-antibiotic combination therapy","volume":"5","author":"Rodriguez-Gonzalez","year":"2020","journal-title":"mSystems"},{"key":"10.1016\/j.addr.2024.115447_b0740","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jtbi.2017.06.037","article-title":"Modeling the synergistic elimination of bacteria by phage and the innate immune system","volume":"429","author":"Leung","year":"2017","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.addr.2024.115447_b0745","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41579-022-00683-3","article-title":"The biogeography of infection revisited","volume":"20","author":"Azimi","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2024.115447_b0750","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41598-017-00529-6","article-title":"Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration","volume":"7","author":"Aljayyoussi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2024.115447_b0755","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153751","article-title":"A spatial quantitative systems pharmacology platform spqsp-io for simulations of tumor-immune interactions and effects of checkpoint inhibitor immunotherapy","volume":"13","author":"Gong","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2024.115447_b0760","doi-asserted-by":"crossref","first-page":"8787","DOI":"10.3748\/wjg.v21.i29.8787","article-title":"Role of the normal gut microbiota","volume":"21","author":"Jandhyala","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.addr.2024.115447_b0765","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature11053","article-title":"Human gut microbiome viewed across age and geography","volume":"486","author":"Yatsunenko","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.addr.2024.115447_b0770","article-title":"Role of the gut microbiota in nutrition and health","volume":"361","author":"Valdes","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.addr.2024.115447_b0775","doi-asserted-by":"crossref","first-page":"1098386","DOI":"10.3389\/fmicb.2023.1098386","article-title":"Role of gut microbiota in infectious and inflammatory diseases","volume":"14","author":"Maciel-Fiuza","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2024.115447_b0780","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1093\/infdis\/jiaa497","article-title":"The gut microbiome as a reservoir for antimicrobial resistance","volume":"223","author":"Anthony","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2024.115447_b0785","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2024.115447_b0790","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1073\/pnas.1000087107","article-title":"Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation","volume":"108","author":"Dethlefsen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2024.115447_b0795","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41586-020-2971-8","article-title":"The gut microbiota is associated with immune cell dynamics in humans","volume":"588","author":"Schluter","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2024.115447_b0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104079","article-title":"Mathematical models to study the biology of pathogens and the infectious diseases they cause","volume":"25","author":"Xavier","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.addr.2024.115447_b0805","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nature13828","article-title":"Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile","volume":"517","author":"Buffie","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2024.115447_b0810","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ismej.2007.3","article-title":"Long-term ecological impacts of antibiotic administration on the human intestinal microbiota","volume":"1","author":"Jernberg","year":"2007","journal-title":"ISME J"},{"key":"10.1016\/j.addr.2024.115447_b0815","doi-asserted-by":"crossref","first-page":"e9836","DOI":"10.1371\/journal.pone.0009836","article-title":"Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome","volume":"5","author":"Jakobsson","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2024.115447_b0820","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cpt.2194","article-title":"Biomarker-guided individualization of antibiotic therapy","volume":"110","author":"Aulin","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2024.115447_b0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106059","article-title":"Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections","volume":"56","author":"Thorsted","year":"2020","journal-title":"Int. J. Antimicrob Agents"},{"key":"10.1016\/j.addr.2024.115447_b0830","first-page":"396","article-title":"Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis","volume":"86","author":"Muller","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2024.115447_b0835","doi-asserted-by":"crossref","unstructured":"Y. Shehabi, M. Sterba, P.M. Garrett, K.S. Rachakonda, D. Stephens, P. Harrigan, A. Walker, M.J. Bailey, B. Johnson, D. Millis, G. Ding, S. Peake, H. Wong, J. Thomas, K. Smith, L. Forbes, M. Hardie, S. Micallef, J.F. Fraser, G.S.I. Pro, ACT Group, Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial, Am. J. Respir Crit. Care Med., 190 (2014) 1102-1110.","DOI":"10.1164\/rccm.201408-1483OC"},{"key":"10.1016\/j.addr.2024.115447_b0840","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/cc7903","article-title":"Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial","volume":"13","author":"Hochreiter","year":"2009","journal-title":"Crit. Care"},{"key":"10.1016\/j.addr.2024.115447_b0845","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1473-3099(17)30592-3","article-title":"Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis","volume":"18","author":"Schuetz","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2024.115447_b0850","article-title":"Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections","volume":"10","author":"Schuetz","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.addr.2024.115447_b0855","doi-asserted-by":"crossref","unstructured":"E. Assink-de Jong, D.W. de Lange, J.A. van Oers, M.W. Nijsten, J.W. Twisk, A. Beishuizen, Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients--calculated sample size: 1816 patients, BMC Infect Dis, 13 (2013) 178.","DOI":"10.1186\/1471-2334-13-178"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X24002692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X24002692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T14:34:30Z","timestamp":1730385270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X24002692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":171,"alternative-id":["S0169409X24002692"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2024.115447","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2024.115447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115447"}}